SynthesisChest2022
BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.
Synthesis in Chest, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Clinical Response to Pulmonary Arterial Hypertension Treatment Does Not Depend on Pulmonary Arterial Wedge Pressure: A Meta-Analysis Using Individual Participant Data from Randomized Clinical Trials.American journal of respiratory and critical care medicine · 2024Pooled it
- Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension.American journal of respiratory and critical care medicine · 2023Pooled it
- Observed Weight Gain in Patients With Pulmonary Arterial Hypertension Treated With Sotatercept.Pulmonary circulation · 2026Article
- Use of Machine-Learning Models to Identify Clinical Features Associated With A Future Clinical Worsening Event in Patients With Pulmonary Arterial Hypertension.Pulmonary circulation · 2026Article
- Inflammation and Obesity Correlate in Pulmonary Hypertension but Are Associated with Diverging Outcomes.American journal of respiratory and critical care medicine · 2026Article
- Artificial intelligence-driven multivariate integration for pulmonary arterial pressure prediction in pulmonary hypertension.NPJ digital medicine · 2025Article
- Article
- Initial Body Weight as an Important Factor for Improving the Reliability and Translational Relevance of the Preclinical Monocrotaline-Induced Rat Pulmonary Hypertension Model.International journal of molecular sciences · 2025Article
- Experimental animal models and patient-derived platforms to bridge preclinical discovery and translational therapeutics in pulmonary arterial hypertension.Journal of translational medicine · 2025Review
- Body Mass Index and Right Ventricular Structure: Insights From Observational and Mendelian Randomization Analyses.Pulmonary circulation · 2025Article
- Acidosis and in-hospital mortality in patients with pulmonary hypertension: a retrospective cohort study based on the MIMIC-IV database.Frontiers in medicine · 2025Article
- Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis.European heart journal · 2024Article
- Electrocardiographic Abnormalities and Their Association with Outcomes in Randomized Clinical Trials of Pulmonary Arterial Hypertension.Annals of the American Thoracic Society · 2024Article
- Win Statistics in Pulmonary Arterial Hypertension Clinical Trials.American journal of respiratory and critical care medicine · 2023Article
- Respiratory complications of obesity: from early changes to respiratory failure.Breathe (Sheffield, England) · 2023Review
- A pilot study to examine association of BMI with functional class and 6 min walk distance in idiopathic and heritable PAH: Possible association with estrogen metabolism.Pulmonary circulation · 2022Article
- Extrapulmonary manifestations of pulmonary arterial hypertension.Expert review of respiratory medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundObesity is increasingly prevalent in pulmonary arterial hypertension (PAH) but is associated with improved survival, creating an "obesity paradox" in PAH. It is unknown if the improved outcomes could be attributable to obese patients deriving a greater benefit from PAH therapies. RESEARCH QUESTION: Does BMI modify treatment effectiveness in PAH? STUDY DESIGN AND
methodsUsing individual participant data, a meta-analysis was conducted of phase III, randomized, placebo-controlled trials of treatments for PAH submitted for approval to the U.S. Food and Drug Administration from 2000 to 2015. Primary outcomes were change in 6-min walk distance (6MWD) and World Health Organization (WHO) functional class.
resultsA total of 5,440 participants from 17 trials were included. Patients with overweight and obesity had lower baseline 6MWD and were more likely to be WHO functional class III or IV. Treatment was associated with a 27.01-m increase in 6MWD (95% CI, 21.58-32.45; P < .001) and lower odds of worse WHO functional class (OR, 0.58; 95% CI, 0.48-0.70; P < .001). For every 1 kg/m
interpretationPatients with overweight and obesity had lower baseline 6MWD and worse WHO functional class than patients with normal weight with PAH. Higher BMI did not modify the treatment response for change in 6MWD, but it attenuated the treatment response for WHO functional class. PAH trials should include participants representative of all weight groups to allow for assessment of treatment heterogeneity and mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.